Perspective

it Medical Team
www.itmedicalteam.pl

Translational Biomedicine
ISSN 2172-0479

2024
Vol.15 No.1:009

Targeted Molecular Therapies in Animals and Humans: A Comparative Study

Manisha Mehra*

Department of Molecular Therapy, Wohs University, Gujarat, India

***Corresponding author:** Manisha Mehra, Department of Molecular Therapy, Wohs University, Gujarat, India; E-mail: manishmeh904@gmail.com

Received date: Jan 09, 2024, Manuscript No. IPTB-24-14458; **Editor assigned date:** Jan 12, 2024, PreQC No. IPTB-24-14458 (PQ); **Reviewed date:** Jan 26, 2024, QC No. IPTB-24-14458; **Revised date:** Feb 07, 2024, Manuscript No. IPTB-24-14458 (R); **Published date:** Feb 15, 2024, Invoice No. IPTB-24-14458

Citation: Mehra M (2024) Targeted Molecular Therapies in Animals and Humans: A Comparative Study. Transl Biomed Vol.15 No.1

Introduction

In the realm of medical research and treatment, targeted therapies have emerged as a revolutionary approach to combat diseases at the molecular level. This paradigm shift in medicine has not only transformed the way we understand diseases but has also paved the way for more effective and less invasive treatments. While targeted therapies have been extensively studied in humans, their application in animals is an area of growing interest and significance.

Description

Targeted therapies

Targeted therapies refer to medical interventions designed to interfere with specific molecules involved in the growth, progression and spread of diseases. Unlike conventional treatments such as chemotherapy, which often affect both healthy and diseased cells, targeted therapies are designed to selectively target abnormal cells, minimizing damage to surrounding healthy tissues.

In human medicine: The evolution of targeted therapies in human medicine has been marked by groundbreaking advancements in understanding the underlying molecular mechanisms of various diseases. Cancer, for instance, has been a primary focus for targeted therapies. The development of drugs that specifically target proteins and pathways involved in cancer cell proliferation has led to improved treatment outcomes and reduced side effects compared to traditional chemotherapy.

One prominent example is the use of Tyrosine Kinase Inhibitors (TKIs) in the treatment of certain types of cancers. These drugs target specific proteins responsible for the uncontrolled growth of cancer cells, disrupting their signaling pathways and inhibiting tumor progression. Imatinib, for instance, has shown remarkable success in the treatment of chronic myeloid leukemia by specifically targeting the BCR-ABL fusion protein.

In addition to cancer, targeted therapies have also proven effective in autoimmune diseases. Monoclonal antibodies, for instance, are designed to target specific components of the immune system, offering a more precise and tailored approach to managing conditions like rheumatoid arthritis and psoriasis.

The success of targeted therapies in human medicine has spurred interest in extending these approaches to veterinary medicine, where similar diseases afflict companion animals and livestock.

In veterinary medicine: The application of targeted therapies in animals has gained traction in recent years, with researchers exploring ways to adapt and implement successful human treatments for veterinary use. One area of particular interest is oncology, as cancer is a leading cause of morbidity and mortality in animals, mirroring its impact in human populations.

Veterinary oncology has seen the development and utilization of targeted therapies such as kinase inhibitors and immunotherapies. In dogs, mast cell tumors are common and the use of tyrosine kinase inhibitors, like toceranib phosphate, has shown promising results in inhibiting the growth of these tumors. Similarly, monoclonal antibodies have been explored for treating certain types of cancers in cats.

Beyond cancer, targeted therapies are being investigated for various other conditions in animals, including autoimmune diseases, inflammatory disorders and infectious diseases. The goal is to provide more effective and less invasive treatments while minimizing side effects and improving the overall quality of life for animals.

Challenges and opportunities

Targeted therapies have revolutionized the treatment landscape for various diseases in both animals and humans, offering the promise of more effective and precise interventions. However, despite their potential, these therapies face distinct challenges in translating success from animal models to human patients.

In the realm of animal targeted therapies, one significant hurdle is the limited availability of preclinical models that accurately represent the complexity of human diseases. While animal models provide valuable insights into the initial safety and efficacy of targeted treatments, the differences between species can sometimes lead to misleading results. The challenge lies in finding animal models that faithfully mimic the molecular and physiological intricacies of human diseases, ensuring a more reliable translation of therapeutic outcomes.

Additionally, variability in individual responses within a species poses challenges in both animals and humans. Genetic diversity, environmental factors and underlying health

© Copyright it Medical Team| This article is available from: https://www.itmedicalteam.pl/translational-biomedicine.html

conditions can influence how individuals respond to targeted therapies. This variability complicates the prediction of treatment outcomes and necessitates a personalized approach to maximize therapeutic benefits.

In human-targeted therapies, challenges emerge during the clinical trial phase. The stringent regulatory requirements, ethical considerations and the need for large, diverse patient populations can lead to prolonged and costly development timelines. Furthermore, human trials often encounter unforeseen adverse effects that were not observed in preclinical animal studies, underscoring the complexities of the human biological system.

Ethical considerations

As targeted therapies continue to advance, ethical considerations become increasingly relevant. In both human and veterinary medicine, questions arise about access to these cutting-edge treatments. The cost, availability and ethical implications of using targeted therapies in animals must be carefully examined to ensure that these advancements benefit all species, not just those with privileged access to healthcare.

Moreover, the ethical dimensions extend to the welfare of animals involved in research and treatment. Striking a balance between advancing medical knowledge and ensuring the well-being of animals requires stringent ethical guidelines and oversight.

Conclusion

The study of targeted therapies in animals and humans represents a frontier in medical research, promising innovative solutions for a myriad of diseases. The successes achieved in human medicine are now inspiring similar breakthroughs in veterinary medicine, offering new hope for improved treatments in companion animals and livestock.

The challenges of translating targeted therapies across species underscore the need for collaborative efforts between medical and veterinary professionals. By sharing knowledge, resources and expertise, researchers can overcome obstacles and unlock the full potential of targeted therapies for the benefit of all living beings.

As we stand at the intersection of human and veterinary medicine, the study of targeted therapies exemplifies the power of interdisciplinary collaboration in advancing medical science and improving the health and well-being of both animals and humans alike.